today announced the presentation of a trial-in-progress poster on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-catenin TCF4 ...
The company also announces its participation in Industry Day 25: Toward Open 6G Networks, hosted by the Institute for The Wireless Internet of Things at Northeastern University. The event will take ...